Compare MIRM & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIRM | ESNT |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.9B |
| IPO Year | 2019 | 2013 |
| Metric | MIRM | ESNT |
|---|---|---|
| Price | $86.88 | $57.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $114.67 | $67.86 |
| AVG Volume (30 Days) | ★ 763.1K | 643.1K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 2.45% |
| EPS Growth | ★ 74.59 | 0.73 |
| EPS | N/A | ★ 6.90 |
| Revenue | $19,138,000.00 | ★ $1,260,935,000.00 |
| Revenue This Year | $26.22 | N/A |
| Revenue Next Year | $21.77 | $3.18 |
| P/E Ratio | ★ N/A | $8.29 |
| Revenue Growth | N/A | ★ 1.45 |
| 52 Week Low | $36.88 | $51.61 |
| 52 Week High | $109.28 | $67.09 |
| Indicator | MIRM | ESNT |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 37.37 |
| Support Level | $85.76 | $56.84 |
| Resistance Level | $96.65 | $61.99 |
| Average True Range (ATR) | 3.90 | 1.01 |
| MACD | -0.38 | -0.00 |
| Stochastic Oscillator | 16.52 | 23.74 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.